/

EDIT

Editas Medicine, Inc.Closed

2.45−0.31 −11.09%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.60 +6.34%

Open

2.73

Prev close

2.75

Day range

2.442.73

52-week range

1.664.33

Volume

2.45M0.98×

Mkt cap

375.50M

P/E ttm

—

Fwd P/E

-3.25

EPS ttm

-0.6800

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−43.53%

Price Chart

Yahoo Finance · delayed

EDITOct 13, 2026O 2.73H 2.73L 2.44C 2.44−0.31 (−11.09%)Vol 2.45M

SMA 502.85
SMA 2002.65

1Y change −31.32% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

EDIT Editas Medicine, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −10.44%
1 month: −9.44%
3 months: −22.63%
6 months: −27.88%
Year to date: +19.27%
1 year: −31.32%

Valuation & ownership

Market cap: 375.50M
Enterprise value: 179.37M
P/E (ttm): —
Forward P/E: -3.25
PEG ratio: —
Price / book: 3.56
Price / sales (ttm): 7.99
EV / EBITDA: -2.21
EPS (ttm): -0.6800
EPS (forward): -0.7531
Beta (5y monthly): 2.00
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 153.58M
Float: 115.49M
Short % of float: 24.21%
Short ratio (days): 12.47
Held by insiders: 0.18%
Held by institutions: 79.37%
Avg volume (3m): 2.50M
50-day average: 2.85
200-day average: 2.65
52-week change: −31.32%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 39.4
vs 50-day SMA: −14.17%
vs 200-day SMA: −7.83%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 8.38%
Realised vol (20d, ann.): 74.2%
From 52-week high: −43.53%
From 52-week low: +47.29%

ANR

Analyst Consensus

10 analysts

Consensus

Buy

1.77 on a 1 (strong buy) – 5 (sell) scale

Mean target

6.10

+149.49% implied

Low 1.00Median 5.50High 15.00

Recommendation trend

Now9 / 2 / 2
1m ago / 3 /

DES

About Editas Medicine, Inc.

Yahoo Finance profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 87
Headquarters: Cambridge, MA, United States
Website: editasmedicine.com
Officers: Dr. Gilmore O'Neill M.D. President, CEO & Director
Ms. Amy Parison Senior VP & CFO
Dr. Linda C. Burkly Ph.D. Executive VP & Chief Scientific Officer

SEAS

Seasonality · EDIT

2016–2026 · monthly returns

Strongest month Jun +8.99%Weakest month Sep −7.64%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-2.9	10.6	12.3	21.5	15.3	-6.4	-20.4	18.6	-16.0	-4.9			+19.3%
2025	3.1	46.6	-39.6	42.2	4.2	27.9	14.1	2.4	35.0	-11.2	-21.8	-14.9	+61.4%
2024	-30.6	43.1	-26.2	-29.8	-0.2	-10.2	15.8	-30.9	-8.8	-15.0	-22.8	-43.3	−87.5%
2023	11.5	-8.6	-19.8	12.6	12.5	-10.3	6.7	1.5	-12.5	-14.4	57.6	-3.8	+14.2%
2022	-28.3	-10.1	11.1	-30.4	-14.0	3.9	34.5	-7.6	-16.7	2.5	-15.5	-16.3	−66.6%
2021	-12.5	-28.5	-4.2	-11.9	-8.3	66.8	-26.1	51.9	-35.4	-10.6	-11.1	-18.7	−62.1%
2020	-10.7	-16.1	-10.6	16.6	17.1	9.3	-0.7	20.0	-20.4	10.3	-1.1	129.2	+136.8%
2019	-4.5	-5.1	18.5	1.2	-17.0	20.4	2.1	-1.7	-8.4	-8.4	45.3	-2.2	+30.2%
2018	18.8	0.4	-9.5	-5.3	22.0	-6.5	-17.0	10.4	-3.1	-20.4	23.0	-27.0	−26.0%
2017	7.3	43.1	-10.5	-15.5	-27.5	22.8	0.8	24.8	13.7	3.3	16.4	6.4	+89.3%
2016			19.3	-4.3	12.2	-34.2	5.4	-34.6	-19.9	4.9	0.9	13.7	−43.9%

INSD

Insider Activity · EDIT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 2, 2026	O Neill Gilmore NeilChief Executive Officer	Sale at price 3.04 per share.	5.1K	$15.56K
Sep 2, 2026	Burkly LindaOfficer	Sale at price 3.04 per share.	709	$2.15K
Sep 2, 2026	Parison AmyChief Financial Officer	Sale at price 3.04 per share.	453	$1.38K
Aug 2, 2026	Parison AmyChief Financial Officer	Sale at price 2.58 per share.	678	$1.75K
Jul 27, 2026	Burkly LindaOfficer	Sale at price 2.67 per share.	4.9K	$13.16K
Jun 2, 2026	O Neill Gilmore NeilChief Executive Officer	Sale at price 2.70 per share.	15.4K	$41.54K
Jun 2, 2026	Burkly LindaOfficer	Sale at price 2.70 per share.	731	$1.98K
Jun 2, 2026	Parison AmyChief Financial Officer	Sale at price 2.70 per share.	464	$1.25K
Mar 2, 2026	O Neill Gilmore NeilChief Executive Officer	Sale at price 2.02 per share.	5.4K	$10.89K
Mar 2, 2026	Burkly LindaOfficer	Sale at price 2.02 per share.	749	$1.51K
Mar 2, 2026	Parison AmyChief Financial Officer	Sale at price 2.02 per share.	474	$957
Dec 2, 2025	O Neill Gilmore NeilChief Executive Officer	Sale at price 2.15 per share.	5.6K	$12.06K
Dec 2, 2025	Burkly LindaOfficer	Sale at price 2.15 per share.	713	$1.53K
Dec 2, 2025	Parison AmyChief Financial Officer	Sale at price 2.15 per share.	461	$993
Sep 2, 2025	O Neill Gilmore NeilChief Executive Officer	Sale at price 2.60 per share.	5.6K	$14.52K
Sep 2, 2025	Burkly LindaOfficer	Sale at price 2.60 per share.	710	$1.84K
Sep 2, 2025	Parison AmyChief Financial Officer	Sale at price 2.60 per share.	458	$1.19K
Aug 6, 2025	Parison AmyChief Financial Officer	Sale at price 2.58 per share.	679	$1.75K
Jul 30, 2025	Burkly LindaOfficer	Sale at price 2.49 per share.	5.1K	$12.76K
Jun 2, 2025	O Neill Gilmore NeilChief Executive Officer	Sale at price 1.72 per share.	15.2K	$26.20K

13F

Investors Holding EDIT

latest 13F filings of 29 followed managers

Investors holding EDIT
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$8.0M	0.01%	2.47M	−38%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

EDIT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

EDIT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Editas Medicine, Inc.

Seasonality · EDIT

Insider Activity · EDIT

Congress Trades · EDIT

Investors Holding EDIT

Investors Holding EDIT

Congress Trades · EDIT

Insider Activity · EDIT

Seasonality · EDIT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Editas Medicine, Inc.

Financial Snapshot

Earnings & Dividends

News